Review Article
Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy
Table 2
FOLFIRINOX regimen in patients with borderline resectable or locally advanced unresectable pancreatic cancer.
| Author | Study design | pts | ORR | Resection rate | R0 resections | 1-year PFS |
| Hosein et al. [16] | Retrospective | 18 | — | 39% | 28% | 83% | Gunturu et al. [17] | Retrospective | 16 | 50% | — | — | — | Peddi et al. [18] | Registry study | 23 | 34% | — | — | 75% | Blazer et al. [19] | Retrospective | 43 | — | 54% | 42% | — | Vasile et al. [20] | Phase II | 32 | 37% | 41% | — | — | Kunzmann et al. [21] | Phase II* | 8 | 63% | 37% | — | — |
|
|
Sequential regimen including FOLFIRINOX and nab-paclitaxel plus gemcitabine.
|